The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer

References

• Pilepich MV, Winter K, Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of Phase III RTOG 85–31. Int. J. Radiat. Oncol. Biol. Phys.61(5), 1285–1290 (2005).
   PubMed Web of Science ®Google Scholar
• Roach III M, Lu J, Pilepich MV et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int. J. Radiat. Oncol. Biol. Phys.47(3), 609–615 (2000).
   PubMed Web of Science ®Google Scholar
• Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N. Engl. J. Med.352(19), 1977–1984 (2005).
   PubMed Web of Science ®Google Scholar
• Messing EM, Manola J, Yao J et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol.7(6), 472–479 (2006).
   PubMed Web of Science ®Google Scholar
• Johansson J-E, Holmberg L, Johansson S, Bergström R, Adami H-O. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA277(6), 467–471 (1997).
   PubMed Web of Science ®Google Scholar
• Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a Phase III randomised trial. Lancet360(9327), 103–108 (2002).
   PubMed Web of Science ®Google Scholar
• Iversen P, Tyrrell CJ, Kaisary AV et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J. Urol.164(5), 1579–1582 (2000).
   PubMed Web of Science ®Google Scholar
• English KM, Steeds R, Jones TH, Channer KS. Testosterone and coronary heart disease: is there a link? QJM90(12), 787–791 (1997).
   PubMed Web of Science ®Google Scholar
• Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer106(3), 581–588 (2006).
   PubMed Web of Science ®Google Scholar
• Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol.24(27), 4448–4456 (2006).
   PubMed Web of Science ®Google Scholar
• Braga-Basaria M, Dobs AS, Muller DC et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J. Clin. Oncol.24(24), 3979–3983 (2006).
   PubMed Web of Science ®Google Scholar
• Salminen EK, Portin RI, Koskinen A, Helenius H, Nurmi M. Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clin. Cancer Res.10(22), 7575–7582 (2004).
   PubMed Web of Science ®Google Scholar
• Jenkins VA, Bloomfield DJ, Shilling VM, Edginton TL. Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study. BJU Int.96(1), 48–53 (2005).
   PubMed Web of Science ®Google Scholar
• Basaria S, Lieb J, Tang AM et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin. Endocrinol (Oxf.)56(6), 779–786 (2002).
   PubMed Web of Science ®Google Scholar
• Berruti A, Dogliotti L, Terrone C et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation. J. Urol.167(6), 2361–2367 (2002).
   PubMed Web of Science ®Google Scholar
• Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J. Urol.171(6 Pt 1), 2272–2276 (2004).
   PubMed Web of Science ®Google Scholar
• Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J. Urol.175(1), 136–139 (2006).
   PubMed Web of Science ®Google Scholar
• Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J. Clin. Oncol.22(13), 2546–2553 (2004).
   PubMed Web of Science ®Google Scholar
• See WA, McLeod D, Iversen P, Wirth M. The bicalutamide Early Prostate Cancer program: demography. Urol. Oncol.6(2), 43–47 (2001).
   PubMedGoogle Scholar
• See WA, Wirth MP, McLeod DG et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J. Urol.168(2), 429–435 (2002).
   PubMed Web of Science ®Google Scholar
• Wirth MP, See WA, McLeod DG et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J. Urol.172(5, Part 1 of 2), 1865–1870 (2004).
   PubMed Web of Science ®Google Scholar
• McLeod DG, Iversen P, See WA et al. Bicalutamide 150 mg plus standard care versus standard care alone for early prostate cancer. BJU Int.97(2), 247–254 (2006).
   PubMed Web of Science ®Google Scholar
• Wirth M, Tyrrell C, Delaere K et al. Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer trial 24 at a median 7 years’ follow-up. Prostate Cancer Prostatic Dis.10, 87–93 (2006).
   Google Scholar
• Iversen P, Johansson JE, Lodding P et al. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years. Scand. J. Urol. Nephrol.40(6), 441–452 (2006).
   PubMed Web of Science ®Google Scholar
• McLeod DG, See WA, Klimberg I et al. The bicalutamide 150 mg Early Prostate Cancer Program: findings of the North American trial at 7.7-year median followup. J. Urol.176(1), 75–80 (2006).
   Google Scholar
• Smith JA Jr, Soloway MS, Young MJ. Complications of advanced prostate cancer. Urology54(Suppl. 6A) 8–14 (1999).
   Google Scholar
• See WA, Tyrrell CJ. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. J. Cancer Res. Clin. Oncol.132(Suppl. 1), S7–S16 (2006).
   PubMed Web of Science ®Google Scholar
• Tyrrell CJ, Payne H, Tammela TL et al. Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Int. J. Radiat. Oncol. Biol. Phys.60(2), 476–483 (2004).
   PubMed Web of Science ®Google Scholar
• Van Poppel H, Tyrrell CJ, Haustermans K et al. Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer. Eur. Urol.47(5), 587–592 (2005).
   PubMed Web of Science ®Google Scholar
• Saltzstein D, Sieber P, Morris T, Gallo J. Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis.8(1), 75–83 (2005).
   PubMed Web of Science ®Google Scholar
• Boccardo F, Rubagotti A, Battaglia M et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J. Clin. Oncol.23(4), 808–815 (2005).
   PubMed Web of Science ®Google Scholar
• Fradet Y, Egerdie B, Andersen M et al. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. Eur. Urol.52(1), 106–114 (2007).
   PubMedGoogle Scholar
• Van Poppel H. Editorial comment on: Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. Eur. Urol.52(1), 115– (2007).
   Google Scholar
• Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J. Urol.169(6), 2008–2012 (2003).
   PubMed Web of Science ®Google Scholar
• Smith MR, McGovern FJ, Zietman AL et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N. Engl. J. Med.345(13), 948–955 (2001).
   PubMed Web of Science ®Google Scholar
• Iversen P, Tammela TLJ, Vaage S et al. A randomised comparison of bicalutamide (‘Casodex’) 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group study no. 6.Eur. Urol.42(3), 204–211 (2002).
   PubMed Web of Science ®Google Scholar
• Fourcade R-O, McLeod D. Tolerability of antiandrogens in the treatment of prostate cancer. UroOncology4(1), 5–13 (2004).
   Google Scholar